

AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions, and listings, of claims in the application.

1. (Currently Amended) A composition comprising an interleukin-2 receptor associated polypeptide, wherein said interleukin-2 receptor associated polypeptide is capable of forming a complex ~~is reactive~~ with the monoclonal antibody produced by the hybridoma PTA-82, and said interleukin-2 receptor associated polypeptide has a molecular weight of about 32,000 to 34,000 daltons as determined by SDS-PAGE.
2. (Cancelled)
3. (Currently Amended) A composition comprising an interleukin-2 receptor associated polypeptide, wherein said interleukin-2 receptor associated polypeptide is capable of forming a complex ~~is reactive~~ with the monoclonal antibody produced by the hybridoma PTA-82, and said interleukin-2 receptor associated polypeptide has a molecular weight of about 26,000 to 28,000 daltons as determined by SDS-PAGE.
4. (Original) A composition comprising the interleukin-2 receptor associated polypeptide of Claim 1, wherein said interleukin-2 receptor associated polypeptide is expressed by cells selected from the group consisting of Kit-225 cells and HuT 102 cells.
5. (Original) A composition comprising the interleukin-2 receptor associated polypeptide of Claim 1, wherein said interleukin-2 associated polypeptide associates with the interleukin-2R α subunit.
- 6.-8. (Cancelled)
9. (Currently Amended) A method for purifying an interleukin-2 receptor associated polypeptide, wherein said method comprises:
 - (a) providing cells expressing an interleukin-2 receptor and an interleukin-2 receptor associated polypeptide,
 - (b) solubilizing the cells to produce a cell extract, and
 - (c) contacting said cell extract ~~cells expressing interleukin-2 receptors and interleukin-2 receptor associated polypeptide,~~ with an anti-interleukin-2 receptor associated

polypeptide antibody, ~~under conditions~~ wherein said antibody forms a complex with said interleukin-2 receptor associated polypeptide expressed by said cells.

10. (Cancelled)

11. (Currently Amended) The method of Claim 9, wherein said anti-interleukin-2 receptor associated polypeptide antibody is present on an immunoaffinity column.

12. (Previously Presented) The method of Claim 11, wherein said interleukin-2 receptor associated protein bound to said anti-interleukin-2 receptor associated polypeptide antibody is eluted from said column.

13. (Currently Amended) The method of Claim 9, wherein said cells expressing said interleukin-2 receptor and said interleukin-2 receptor associated polypeptide are selected from the group consisting of ~~cells~~ cell lines expressing interleukin-2R α and cell lines expressing interleukin-2R β subunits.

14. (Original) The interleukin-2 receptor associated polypeptide of Claim 13, wherein said interleukin-2 receptor expressing cells are Kit 225 cells.

15. (Original) A composition comprising an interleukin-2 receptor associated polypeptide purified by the method of Claim 9.

16.-21. (Cancelled)

22. (Previously Presented) A composition comprising the interleukin-2 receptor associated polypeptide of Claim 3, wherein said interleukin-2 receptor associated polypeptide is expressed by cells selected from the group consisting of Kit-225 cells and HuT 102 cells.

23. (Previously Presented) A composition comprising the interleukin-2 receptor associated polypeptide of Claim 3, wherein said interleukin-2 associated polypeptide associates with the interleukin-2 R α subunit.

24. (New) A composition comprising an interleukin-2 receptor associated polypeptide, wherein said interleukin-2 receptor associated polypeptide is capable of forming a complex with the monoclonal antibody produced by the hybridoma PTA-82, and

said interleukin-2 receptor associated polypeptide has a molecular weight of 32,000 to 34,000 daltons as determined by SDS-PAGE.

25. (New) A composition comprising an interleukin-2 receptor associated polypeptide, wherein said interleukin-2 receptor associated polypeptide is capable of forming a complex with the monoclonal antibody produced by the hybridoma PTA-82, and said interleukin-2 receptor associated polypeptide has a molecular weight of 26,000 to 28,000 daltons as determined by SDS-PAGE.